Pharmaceutical Executive-12-01-2013

For Patrick Lindsay, providing decision support across the full product life cycle is no stretch goal-it's today's fact of life

A patient-centric approach to drug development delivers the benefits that actually create value, writes Charlotte Vansgaard and Mikkel Brok-Kristensen.

For senior executives, meeting the requirements of a Consent Decree to the satisfaction of regulators is only half of the job.

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.

"Science powers commerce," Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the Prime Minister summarizes a massive effort by various stakeholders to create a "brain gain" in Canada to strengthen its positioning in the world of research and technology. Despite declining investments by big pharma in recent years, the country has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market.